Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
291 stopped studies mapped to Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and descendants · 82% state a reason
Over the 291 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01500161 | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing… | Phase 2 | terminated | Dec 28, 2011 | Texas Oncology Cancer Center | Insufficient accruals | Enrollment / accrual |
| NCT00301769 | SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic… | Phase 1 | terminated | Mar 13, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00612612 | Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated… | Phase 1 | terminated | Feb 11, 2008 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00947388 | Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) | Phase 1 | terminated | Jul 28, 2009 | Case Comprehensive Cancer Center | No more eligible patients | Other (stated, no rule matched) |
| NCT00872976 | Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia | Phase 1 | withdrawn | Apr 1, 2009 | Bristol-Myers Squibb | Business Objectives Changed | Sponsor / business decision |
| NCT00377104 | Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small… | Phase 1 | terminated | Sep 15, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00079443 | FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With… | Phase 2 | terminated | Mar 10, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00009984 | Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer | Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00098488 | 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients… | Phase 1 | terminated | Dec 8, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00103272 | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With… | Phase 1 | terminated | Feb 8, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00354185 | PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic… | Phase 1 | terminated | Jul 20, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00005786 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia | N/A | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00060112 | Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma | Phase 1 | terminated | May 7, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00086840 | CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | Phase 2 | terminated | Jul 12, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00005950 | 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell… | Phase 2 | terminated | Apr 20, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00101244 | SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's… | Phase 1 | terminated | Jan 10, 2005 | National Cancer Institute (NCI) | Administratively Complete. | Other (stated, no rule matched) |
| NCT00636155 | EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Phase 2 | terminated | Mar 14, 2008 | David Rizzieri | funding | Funding |
| NCT00108108 | Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is… | Phase 1 | terminated | Apr 15, 2005 | Novartis Pharmaceuticals | Slow enrollment and minimal preliminary biological and clinical efficacy. | Efficacy / futility |
| NCT01659047 | A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single… | Phase 2 | withdrawn | Aug 7, 2012 | Gilead Sciences | not stated | Not stated |
| NCT00038818 | CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell… | N/A | terminated | Jun 7, 2002 | M.D. Anderson Cancer Center | Low accrual. | Enrollment / accrual |
| NCT00962715 | Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon… | Phase 1 / Phase 2 | withdrawn | Aug 20, 2009 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00081887 | Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic… | Phase 1 | terminated | Apr 27, 2004 | M.D. Anderson Cancer Center | low accrual | Enrollment / accrual |
| NCT00800566 | Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL) | Phase 1 | withdrawn | Dec 2, 2008 | M.D. Anderson Cancer Center | Sponsor terminated. | Other (stated, no rule matched) |
| NCT01558778 | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem… | N/A | withdrawn | Mar 20, 2012 | Roswell Park Cancer Institute | device not available | Other (stated, no rule matched) |
| NCT00151736 | Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of… | Phase 2 | terminated | Sep 9, 2005 | Cephalon | not stated | Not stated |
| NCT00758693 | Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or… | Phase 2 | withdrawn | Sep 25, 2008 | University of Kentucky | Funding was withdrawn due to insufficient accrual | Enrollment / accrual |
| NCT00504491 | R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia(R-CHOP) | Phase 2 | withdrawn | Jul 20, 2007 | CABYC | IMP new owner decision | Other (stated, no rule matched) |
| NCT01127542 | RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial(RESPeCT) | Phase 2 | terminated | May 21, 2010 | The Christie NHS Foundation Trust | Potential safety issue of second primary malignancies in patients treated with lenalidomide. | Safety / toxicity |
| NCT00524667 | HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia | Phase 2 | terminated | Sep 3, 2007 | CancerCare Manitoba | Terminated due to poor accrual. | Enrollment / accrual |
| NCT01125787 | Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic… | Phase 2 | terminated | May 18, 2010 | Nevada Cancer Institute | Low enrollment | Enrollment / accrual |
| NCT01131247 | PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a… | Phase 2 | withdrawn | May 26, 2010 | Nevada Cancer Institute | PI left institution | Investigator |
| NCT01116154 | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin… | Phase 1 | terminated | May 4, 2010 | City of Hope Medical Center | Sponsor withdrew support for the study | Other (stated, no rule matched) |
| NCT00646165 | Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia | Phase 1 | terminated | Mar 28, 2008 | Mundipharma Research Limited | Poor recruitment and change in development strategy | Enrollment / accrual |
| NCT00319930 | Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL | Phase 1 | terminated | Apr 27, 2006 | Biogen | Discontinuation of program | Other (stated, no rule matched) |
| NCT00918450 | Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic… | Phase 2 | withdrawn | Jun 11, 2009 | Abbott | Sponsor has decided to not proceed with this study. | Other (stated, no rule matched) |
| NCT00344786 | Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL | Phase 1 | terminated | Jun 27, 2006 | Biogen | Sponsor's decision | Sponsor / business decision |
| NCT00485966 | Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell… | Phase 2 | withdrawn | Jun 13, 2007 | Cylene Pharmaceuticals | This study was withdrawn prior to patient enrollment | Enrollment / accrual |
| NCT00676871 | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous… | Phase 1 / Phase 2 | withdrawn | May 13, 2008 | MedImmune LLC | Replacing this trial with a new trial. | Other (stated, no rule matched) |
| NCT00234481 | Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia | Phase 1 | terminated | Oct 7, 2005 | Exelixis | Study closed due to slow enrollment | Enrollment / accrual |
| NCT00302861 | A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic… | Phase 1 / Phase 2 | terminated | Mar 15, 2006 | Genitope Corporation | not stated | Not stated |
| NCT00083473 | A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia | Phase 2 | terminated | May 26, 2004 | Titan Pharmaceuticals | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Nov 25, 2013source: clinicaltrials